Glenmark receives DCGI nod to conduct clinical trials of its molecule on cancer patients

The Mumbai-based drug major said, GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pluXSP6
via IFTTT